Novo Nordisk A/S (NVO) Reports Positive Results From First Phase 3 Trial With N8-GP, A Long-Acting Factor VIII For Treatment Of Haemophilia A
3/19/2014 9:49:45 AM
Bagsvaerd, Denmark, March 19, 2014 (GLOBE NEWSWIRE) -- Novo Nordisk today announced the completion of pathfinder(TM)2, the first phase 3 trial with long-acting recombinant factor VIII, N8-GP (turoctocog alfa pegol) for haemophilia A patients. Pathfinder(TM)2 is a multi-national trial evaluating safety and efficacy of N8-GP, when administered for prophylaxis and on-demand treatment in patients with haemophilia A, who are 12 years or older.
Help employers find you! Check out all the jobs and post your resume.
comments powered by